Targeting NF- κB-Mediated Inflammatory Pathways in Cisplatin-Resistant NSCLC

Lung cancer remains a significant health care burden, accounting for 11.6% (2.094 million) of all cancer cases and 18.4% (1.8 million) of cancer related deaths [1]. With advances in targeted therapeutics and immunotherapy agents [2], five-year survival rates are improving with recent SEER data indicating a rate of 19.4% [3]. However, chemotherapy is still widely used, with more recent trials combining traditional chemotherapy with newer agents [4]. Cisplatin, cis-Diamineplatinum (II) dichloride, is a common chemotherapeutic agent used in the treatment of advanced NSCLC [5 –9], and is currently one of the most effective chemotherapeutic agents available, with response rates of 40-50% depending on NSCLC sub-type [10,11].

Source: Lung Cancer - July 11, 2019 Category: Cancer & Oncology Authors: Sarah-Louise Ryan, Sam Beard, Martin P. Barr, Kazou Umezawa, Susan Heavey, Peter Godwin, Steven G. Gray, David Cormican, Stephen P. Finn, Kathy A. Gately, Anthony M. Davies, Erik W. Thompson, Derek J. Richard, Kenneth J. O ’Byrne, Mark N. Adams, Anne-Ma Source Type: research